Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 23:12:724331.
doi: 10.3389/fimmu.2021.724331. eCollection 2021.

Functional Fc Gamma Receptor Gene Polymorphisms and Long-Term Kidney Allograft Survival

Markus Wahrmann  1 , Bernd Döhler  2 , Marie-Luise Arnold  3 , Sabine Scherer  2 , Katharina A Mayer  1 , Susanne Haindl  1 , Helmuth Haslacher  4 , Georg A Böhmig  1 , Caner Süsal  2
Affiliations

Functional Fc Gamma Receptor Gene Polymorphisms and Long-Term Kidney Allograft Survival

Markus Wahrmann et al. Front Immunol. .

Abstract

The functional Fc gamma receptor (FcγR) IIIA polymorphism FCGR3A-V/F158 was earlier suggested to determine the potential of donor-specific HLA antibodies to trigger microcirculation inflammation, a key lesion of antibody-mediated renal allograft rejection. Associations with long-term transplant outcomes, however, have not been evaluated to date. To clarify the impact of FCGR3A-V/F158 polymorphism on kidney transplant survival, we genotyped a cohort of 1,940 recipient/donor pairs. Analyzing 10-year death-censored allograft survival, we found no significant differences in relation to FCGR3A-V/F158. There was also no independent survival effect in a multivariable Cox model. Similarly, functional polymorphisms in two other activating FcγR, FCGR2A-H/R131 (FcγRIIA) and FCGR3B-NA1/NA2 (FcγRIIIB), were not associated with outcome. There were also no significant survival differences among patient subgroups at increased risk of rejection-related injury, such as pre-sensitized recipients (> 0% panel reactivity; n = 438) or recipients treated for rejection within the first year after transplantation (n = 229). Our study results suggest that the earlier shown association of FcγR polymorphism with microcirculation inflammation may not be strong enough to exert a meaningful effect on graft survival.

Keywords: Fc gamma receptor; allograft survival; anti-HLA antibodies; antibody-mediated rejection; kidney transplantation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Death-censored graft survival (A), overall graft survival (B), and patient survival (C) for genotypic groups of FCGR3A-V/F158 (total 1,940 recipients).
Figure 2
Figure 2
FCGR3A-V/F158 polymorphism in relation to 1-year serum creatinine [(A) total 1,676 recipients] and treated rejection episodes within the first year after transplantation [(B) total 1,010 recipients].
Figure 3
Figure 3
Death-censored graft survival among (A) 438 pre-sensitized recipients (panel reactivity > 0%) and (B) 229 recipients with treated rejection during the first-post-transplant year, in relation to FCGR3A-V/F158 genotype.
Figure 4
Figure 4
Impact of donor-derived FcγRIIIA polymorphism on death-censored graft survival (total 1,940 recipients).
See this image and copyright information in PMC

References

    1. Loupy A, Lefaucheur C. Antibody-Mediated Rejection of Solid-Organ Allografts. N Engl J Med (2018) 379(12):1150–60. 10.1056/NEJMra1802677 - DOI - PubMed
    1. Böhmig GA, Eskandary F, Doberer K, Halloran PF. The Therapeutic Challenge of Late Antibody-Mediated Kidney Allograft Rejection. Transpl Int (2019) 32(8):775–88. 10.1111/tri.13436 - DOI - PMC - PubMed
    1. Opelz G, Graver B, Mickey MR, Terasaki PI. Lymphocytotoxic Antibody Responses to Transfusions in Potential Kidney Transplant Recipients. Transplantation (1981) 32(3):177–83. 10.1097/00007890-198109000-00002 - DOI - PubMed
    1. Kerman RH, Van Buren CT, Lewis RM, DeVera V, Baghdahsarian V, Gerolami K, et al. . Improved Graft Survival for Flow Cytometry and Antihuman Globulin Crossmatch-Negative Retransplant Recipients. Transplantation (1990) 49(1):52–6. 10.1097/00007890-199001000-00011 - DOI - PubMed
    1. Wiebe C, Gibson IW, Blydt-Hansen TD, Karpinski M, Ho J, Storsley LJ, et al. . Evolution and Clinical Pathologic Correlations of De Novo Donor-Specific HLA Antibody Post Kidney Transplant. Am J Transplant (2012) 12(5):1157–67. 10.1111/j.1600-6143.2012.04013.x - DOI - PubMed

Publication types